Zenocutuzumab shows clinical benefit in rare bile duct cancer
Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led to responses in more than a third of patients with neuregulin 1 (NRG1)-positive cholangiocarcinoma, ...
Oct 22, 2025
0
0









